TAF11L3: A Potential Drug Target and Biomarker for TATA-Binding Proteins

Target Name: TAF11L3

NCBI ID: G646103

TAF11L3

Other Name(s): TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa pseudogene | TATA-box binding protein associated factor 11 like 3

TAF11L3: A Potential Drug Target and Biomarker for TATA-Binding Proteins

The TATA-binding protein (TBP) is a key regulator of gene expression in various organisms, including humans. TBP plays a crucial role in promoting the loading of RNA polymerase II (RNA polymerase II) onto the nuclear chromatin by interaction with the TATA box, a region of DNA known to play a direct role in the initiation of gene expression. TAF11L3, also known as TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, and 28kDa pseudogene, is a protein that is highly conserved across various species, including humans. TAF11L3 has been identified as a potential drug target and biomarker due to its unique structure and function.

Structure and Function

TAF11L3 is a 28kDa protein that contains 115 amino acid residues. The protein has a unique 51% polyglutamic acid (PGA) sequence at its C-terminus, which is known as the TAF11L3-specific PGA domain. This domains is responsible for the protein's stability and functions as a binding protein.

TAF11L3 functions as a TBP-associated factor, which means it interacts with the TBP protein. The interaction between TAF11L3 and TBP is critical for the regulation of gene expression, as TBP plays a crucial role in the loading of RNA polymerase II onto the nuclear chromatin.

Furthermore, TAF11L3 is involved in the regulation of DNA replication, cell growth, and apoptosis. It has been shown to be involved in the regulation of the replication of the T-cell receptor (TCR), a critical element in the immune response.

TAF11L3 has also been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism for the elimination of damaged or dysfunctional cells. The loss of TAF11L3 has been linked to the development of certain diseases, including cancer.

Drug Target Potential

The TAF11L3-specific PGA domain is a potential drug target for small molecules. This domain is involved in the regulation of various cellular processes, including the regulation of protein stability and DNA replication. Therefore, small molecules that can modulate the activity of TAF11L3, such as inhibitors of DNA replication or inhibitors of protein stability, may be effective in treating various diseases.

Biomarker Potential

The TAF11L3 protein is a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The loss of TAF11L3 has been linked to the development of these diseases, and Therefore, TAF11L3 may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

TAF11L3 is a protein that has unique structure and function, including its 51% PGA domain, which is responsible for its stability and interactions with the TBP protein. It is involved in the regulation of various cellular processes, including the regulation of DNA replication, cell growth, and apoptosis. Therefore, TAF11L3 may be a potential drug target and biomarker for various diseases. Further studies are needed to fully understand the role of TAF11L3 in the regulation of gene expression and the development of various diseases.

Protein Name: TATA-box Binding Protein Associated Factor 11 Like 3

The "TAF11L3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF11L3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets